ASX:MVF

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. More Details


Snowflake Analysis

Undervalued with adequate balance sheet.

Share Price & News

How has Monash IVF Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MVF has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

MVF

-3.9%

AU Healthcare

-3.9%

AU Market


1 Year Return

-42.5%

MVF

-0.4%

AU Healthcare

-9.6%

AU Market

Return vs Industry: MVF underperformed the Australian Healthcare industry which returned -0.4% over the past year.

Return vs Market: MVF underperformed the Australian Market which returned -9.6% over the past year.


Shareholder returns

MVFIndustryMarket
7 Day0%-3.9%-3.9%
30 Day-9.4%-0.6%1.8%
90 Day9.5%4.4%1.7%
1 Year-37.0%-42.5%1.5%-0.4%-6.4%-9.6%
3 Year-55.0%-63.1%16.7%7.3%12.3%-1.9%
5 Year-48.1%-61.3%21.5%5.0%40.0%11.3%

Price Volatility Vs. Market

How volatile is Monash IVF Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Monash IVF Group undervalued compared to its fair value and its price relative to the market?

16.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MVF (A$0.58) is trading below our estimate of fair value (A$0.69)

Significantly Below Fair Value: MVF is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: MVF is good value based on its PE Ratio (12.6x) compared to the AU Healthcare industry average (30.2x).

PE vs Market: MVF is good value based on its PE Ratio (12.6x) compared to the Australian market (20.5x).


Price to Earnings Growth Ratio

PEG Ratio: MVF is good value based on its PEG Ratio (0.7x)


Price to Book Ratio

PB vs Industry: MVF is good value based on its PB Ratio (0.9x) compared to the AU Healthcare industry average (1.4x).


Next Steps

Future Growth

How is Monash IVF Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

19.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MVF's forecast earnings growth (19% per year) is above the savings rate (2.3%).

Earnings vs Market: MVF's earnings (19% per year) are forecast to grow faster than the Australian market (17.6% per year).

High Growth Earnings: MVF's earnings are forecast to grow, but not significantly.

Revenue vs Market: MVF's revenue (5.4% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: MVF's revenue (5.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MVF's Return on Equity is forecast to be low in 3 years time (8.3%).


Next Steps

Past Performance

How has Monash IVF Group performed over the past 5 years?

-10.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MVF has high quality earnings.

Growing Profit Margin: MVF's current net profit margins (8.1%) are lower than last year (13.1%).


Past Earnings Growth Analysis

Earnings Trend: MVF's earnings have declined by 10.5% per year over the past 5 years.

Accelerating Growth: MVF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MVF had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Healthcare industry average (-8.1%).


Return on Equity

High ROE: MVF's Return on Equity (4.7%) is considered low.


Next Steps

Financial Health

How is Monash IVF Group's financial position?


Financial Position Analysis

Short Term Liabilities: MVF's short term assets (A$30.7M) do not cover its short term liabilities (A$37.9M).

Long Term Liabilities: MVF's short term assets (A$30.7M) do not cover its long term liabilities (A$59.0M).


Debt to Equity History and Analysis

Debt Level: MVF's debt to equity ratio (7.5%) is considered satisfactory.

Reducing Debt: MVF's debt to equity ratio has reduced from 74.2% to 7.5% over the past 5 years.

Debt Coverage: MVF's debt is well covered by operating cash flow (164.1%).

Interest Coverage: MVF's interest payments on its debt are well covered by EBIT (3.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Monash IVF Group current dividend yield, its reliability and sustainability?

5.78%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MVF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MVF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MVF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MVF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MVF is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MVF's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Michael Knaap

2yrs

Tenure

AU$561,448

Compensation

Mr. Michael D. Knaap serves as Chief Executive Officer, Managing Director and Director of Monash IVF Group Limited since April 15, 2019. Mr. Knaap served as an Interim Chief Executive Officer of Monash IVF ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD395.14K) is about average for companies of similar size in the Australian market ($USD519.52K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Knaap
CEO, MD & Director2yrsAU$561.45k0.039%
A$ 86.6k
Malik Jainudeen
Group CFO & Company Secretary1.42yrsAU$321.96k0.0049%
A$ 11.1k
Hamish Hamilton
Chief Operating Officer0.58yrAU$990.86k0.018%
A$ 41.1k
Richard Henshaw
Executive Director6.42yrsAU$346.95k0.35%
A$ 781.3k
Pierre Haila
Chief Information Officer & Chief Project Officer2.75yrsno datano data
Fiona Allen
Chief Marketing Officer1.25yrsno datano data
Peggy North
Chief People & Culture Officerno datano datano data
Denise Donati
CEO & Clinic Manager of Fertility Solutionsno datano datano data
Clementina Singh
General Manager of New South Wales2.75yrsno datano data

1.7yrs

Average Tenure

Experienced Management: MVF's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Knaap
CEO, MD & Director2yrsAU$561.45k0.039%
A$ 86.6k
Richard Henshaw
Executive Director6.42yrsAU$346.95k0.35%
A$ 781.3k
Neil Broekhuizen
Independent Non-Executive Director6.25yrsAU$95.16k0.034%
A$ 76.4k
Josef Czyzewski
Independent Non-Executive Director6.25yrsAU$111.71k0.062%
A$ 138.8k
Richard Davis
Independent Chairman6.25yrsAU$156.19k0.047%
A$ 104.7k
Zita Peach
Independent Non-Executive Director4yrsAU$95.16k0.024%
A$ 53.4k
Catherine West
Independent Non-Executive Directorno datano datano data

6.3yrs

Average Tenure

65yo

Average Age

Experienced Board: MVF's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 65.2%.


Top Shareholders

Company Information

Monash IVF Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Monash IVF Group Limited
  • Ticker: MVF
  • Exchange: ASX
  • Founded: 2014
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: AU$224.040m
  • Shares outstanding: 389.63m
  • Website: https://www.monashivfgroup.com.au

Number of Employees


Location

  • Monash IVF Group Limited
  • Pelaco Building 1
  • Level 1
  • Richmond
  • Victoria
  • 3121
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MVFASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2014
MVFCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2014
MISDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2014

Biography

Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnosis and treatment of infertility, fertility research and tr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/31 10:41
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.